Ventricular Arrhythmias
Ott1
1Sarver Heart Center, University of Arizona Health Sciences Center, 1501 N Campbell Ave, Tucson, AZ 85724, USA. Ottp@U.Arizona.edu
Insights
Implantable cardioverter-defibrillators (ICDs) are first-line therapy for secondary prevention of ventricular arrhythmias (VAs). ICDs also reduce mortality for primary prevention in high-risk myocardial infarction patients.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Background:
- Recent clinical trials provide evidence for managing ventricular arrhythmias (VAs).
- The role of implantable cardioverter-defibrillators (ICDs) and antiarrhythmic drugs is evolving.
- Risk stratification is crucial for preventing sudden cardiac death.
Purpose of the Study:
- To outline an evidence-based approach to ventricular arrhythmias.
- To define the optimal use of ICDs and antiarrhythmic drugs for primary and secondary prevention.
- To discuss alternative therapies like catheter ablation for specific VA types.
Main Methods:
- Review of recent clinical trial data.
- Analysis of survival outcomes for different treatment strategies.
- Evaluation of primary and secondary prevention efficacy.
Main Results:
- ICDs are first-line for secondary prevention of potentially lethal VAs.
- Antiarrhythmic drug selection does not improve survival in secondary prevention.
- ICDs reduce mortality in high-risk post-myocardial infarction patients for primary prevention.
- Catheter ablation is highly effective for monomorphic VAs without heart disease.
Conclusions:
- ICDs are crucial for both secondary prevention and selected primary prevention of VAs.
- Antiarrhythmic drugs have a limited role in improving survival for VA.
- Catheter ablation offers a successful alternative for specific VA patient groups.
Abstract:
Results of recent clinical trials allow an evidence-based approach to ventricular arrhythmias (VAs). The implantable cardioverter-defibrillator (ICD) has clearly established its role in the secondary prevention of VA and should be considered first-line therapy in patients surviving episodes of potentially lethal VAs. It has also been clearly shown that in these patients, antiarrhythmic drug selection by means of serial Holter recording or electrophysiologic study does not improve survival. Antiarrhythmic drug therapy (including amiodarone) as primary prevention in high-risk patients (eg, those who have experienced a myocardial infarction or who have heart failure) has thus far not reduced the mortality rate. In contrast, use of the ICD as a primary preventative strategy has reduced the mortality rate in patients after myocardial infarction who have reduced left ventricular function, nonsustained ventricular tachycardia, and inducible ventricular tachycardia during electrophysiologic study. Thus, patients fitting this clinical profile are best served by implantation of an ICD. Monomorphic ventricular tachycardia occurs rarely in patients without heart disease. These arrhythmias are best treated with catheter ablation therapy, a treatment with a high rate of success and a low rate of complications.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias II: Classification of Tachyarrhythmias
Dysrhythmias III: Characteristics of Dysrhythmias
Dysrhythmias IV: Characteristics of Bradyarrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias


